Cargando…
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
SUMMARY: Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels of biochemical markers of bone formation and resorption. The vertebral anti-fracture e...
Autores principales: | Collette, J., Bruyère, O., Kaufman, J. M., Lorenc, R., Felsenberg, D., Spector, T. D., Diaz- Curiel, M., Boonen, S., Reginster, J.-Y. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801841/ https://www.ncbi.nlm.nih.gov/pubmed/19436941 http://dx.doi.org/10.1007/s00198-009-0940-z |
Ejemplares similares
-
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
por: Reginster, J-Y., et al.
Publicado: (2011) -
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
por: Meunier, P. J., et al.
Publicado: (2009) -
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis
por: Hiligsmann, M., et al.
Publicado: (2013) -
Cardiac concerns associated with strontium ranelate
por: Reginster, Jean-Yves
Publicado: (2014) -
Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice
por: Donneau, A.-F., et al.
Publicado: (2013)